Influenza vaccination effectiveness, unmeasured confounding, and immunomodulatory treatment

Journal of Infectious Diseases

Volumn 209, Issue 8, 2014, Pages 1300-1301

  Fedson, David S ^a  

^a NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; INFLUENZA VACCINE; METFORMIN;

CHRONIC DISEASE; CONFOUNDING VARIABLE; DIABETES MELLITUS; DRUG EFFICACY; HOSPITALIZATION; HUMAN; IMMUNOMODULATION; INFLUENZA VACCINATION; LETTER; MORTALITY; OBSERVATIONAL STUDY; PANDEMIC INFLUENZA; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; SEASONAL INFLUENZA; SEPSIS;

FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; PANDEMICS;

EID: 84897444744     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit809     Document Type: Letter

References (11)

1. Bateman AC, Kieke BA, Irving SA, Meece JK, Shay DK, Belongia EA. Effectiveness of monovalent 2009 pandemic influenza A virus subtype H1N1 and 2010-2011 trivalent inactivated influenza vaccines in Wisconsin during the 2010-2011 influenza season. J Infect Dis 2013; 207:1262-9.
2. Fedson DS.Vaccination effectiveness, unmeasured confounding, and immunomodulatory treatment. J Infect Dis 2014; 209:1300-1.
3. Irving SA, Donahue JG, Shay DK, Ellis-Coyle TLBelongia EA. Evaluation of self-reported and registry-based influenza vaccination status in a Wisconsin cohort. Vaccine 2009; 27: 6546-9.
4. Belongia EA, Kieke BA, Donahue JG, et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 2009; 199:159-167.
5. Belongia EA, Irving SA, Waring SC, et al. Clinical characteristics and 30-day outcomes for influenza A 2009 (H1N1), 2008-2009 (H1N1), and 2007-2008 (H3N2) infections. JAMA 2010; 304:1091-8.
6. Belongia EA, Kieke BA, Donahue JG, et al. Influenza vaccine effectiveness in Wisconsin during the 2007-08 season: Comparison of interim and final results. Vaccine 2011; 29: 6558-63.
7. Fleming DM, Verlander NQ, Elliot AJ, et al. An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998-1999 to 2005-2006. Epidemiol Infect 2010; 138:1281-8.
8. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: A cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 2009; 67:99-109.
9. Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine 2013; 31:3104-9.
10. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 2013; 31:2165-8.
11. De Serres G, Skowronski D, Wu X, Ambrose C. The test-negative design: Validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials. Euro Surveill 2013 Sep 12;18(37). pii: 20585. PubMed PMID: 24079398.